TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All subjects must give written informed consent by parent or guardian~* Male or female subjects, \> 6 - 17 years~* Patients must have endoscopic or radiographic confirmed Crohn's Disease.~* Patients must have a Pediatric Crohn's Disease Activity Index (PCDAI) of at least 31.~Exclusion Criteria:~* Adolescent women of childbearing potential and / or sexually active unless surgically sterile or using adequate contraception (either IUD, oral or deport contraceptive, or barrier plus spermicide), and willing and able to continue contraception for 3 months after the completion of the study.~* Adolescent women who are pregnant or breastfeeding~* Subjects with an ostomy or ileocolic anastomosis from surgery as these operations interfere with the PCDAI assessment~* Subjects taking tacrolimus, cyclosporin, mycophenolate, or anti-TNF-α therapy must be discontinued 4 weeks prior to study initiation.~* Patients with abnormal liver function tests~* Prednisone greater than 10 mg or \> 0.2 mg/kg orally

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Sugar pill (Type: PLACEBO_COMPARATOR): Subjects will receive placebo for for the first 8 weeks administered orally one time daily. After 8 weeks placebo treated subjects are then crossed over to active drug naltrexone 0.1 mg/kg not to exceed 4.5 mg PO once daily for an additional 8 weeks.
- Naltrexone (Type: EXPERIMENTAL): Naltrexone 0.1 mg/kg (not to exceed 4.5mg) once a day orally either in capsules or liquid blinded for 8 weeks followed by open-labeled naltrexone for an additional 8 weeks. Safety and toxicity will be compared to placebo. Also change in Crohn's activity index scores of naltrexone to placebo are compared.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Practice Guidelines Grading Systems

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Pediatricians and residents in pediatrics~Exclusion Criteria:~* Less than six months in clinical practice

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- GRADE system (Type: OTHER): A clinical recommendation built and graded with the GRADE working group system
- SIGN grading system (Type: OTHER): A clinical recommendation built and graded with the Scottish Intercollegiate Guidelines Network system
- NICE grading system (Type: OTHER): A clinical recommendation built and graded with National Institute of Clinical Excellence grading system
- CEBM-Oxford (Type: OTHER): A clinical recommendation built and graded with the Centre for Evidence-Based Medicine grading system

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RCT: Triple vs Sequential vs Concomitant Therapy H Pylori

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* consecutive patients newly diagnosed to have H. pylori infection.~Exclusion Criteria:~* known allergy to any of the treatment drugs~* inability to undergo routine test to confirm success of H. pylori eradication~* previous H. pylori therapy.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- triple therapy (Type: ACTIVE_COMPARATOR): 10 day triple therapy (PPI, amoxicillin 1g, clarithromycin 500mg twice daily)
- Concomitant therapy (Type: ACTIVE_COMPARATOR): 10-day concomitant therapy (PPI, amoxicillin 1g, clarithromycin 500mg, metronidazole 400mg twice daily).
- sequential therapy (Type: ACTIVE_COMPARATOR): 10-day sequential therapy (PPI and amoxicillin 1 g twice daily x 5 days followed by PPI, clarithromycin 500mg, metronidazole 400mg twice daily x 5days)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telbivudine Therapy in HBeAg-positive Pregnant Women to Prevent Mother-to-infant Transmission of HBV

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* pregnant women at 28-32 weeks of gestation~* both HBsAg and HBeAg positive~* good compliance~Exclusion Criteria:~* Coinfection of HAV, HCV, HEV, HIV, and STD~* With history of antiviral treatment against HBV~* With chronic disease, such as heart and kidney disease, asthma, diabetes, hyperthyroidism, severe anemia, bleeding disease, autoimmune diseases~* With threatened miscarriage or relevant treatment during the pregnancy~* With pregnant complications such as pregnancy hypertension, preeclampsia, etc~* With history of fetal deformity, or fetal deformity detected by ultrasound examination~* With ALT \>10 times upper limit, or total bilirubin \>3 times upper limit, of normal value

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Telbivudine (Type: EXPERIMENTAL): HBsAg- and HBeAg-positive pregnant women at 28-32 weeks of gestation start to orally take telbivudine (600 mg/day) until 4 weeks after delivery. Newborn infants receive standard immunoprophylaxis.
- Control (Type: NO_INTERVENTION): Infants of HBsAg- and HBeAg-positive women who are not treated with telbivudine and any other antiviral agents serve as controls. The infants are administered standard immunoprophylaxis against mother-to-infant transmission of HBV, 100-200 IU hepatitis B immunoglobulin (HBIG) within 12 hours after birth and three doses hepatitis B vaccine at 0, 1 and 6-month schedule.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Eastern Cooperative Oncology Group (ECOG) performance status ≤2~* Documented evidence of active multiple myeloma:~  * Newly diagnosed, not candidate for transplant~ * Relapsed/refractory who have received up to 3 prior lines of therapy~* Prior Lenalidomide exposure is permitted only if the following criteria are fulfilled:~  * Not refractory to prior Lenalidomide which is defined as no progression while receiving Lenalidomide or within 60 days of last dose of Lenalidomide~ * Subject did not discontinue Lenalidomide due to a Grade ≥3 related adverse event (AE)~Exclusion Criteria:~* Target Disease Exceptions~  * Plasma cell leukemia~ * Monoclonal gammopathy of undetermined significance (MGUS)~ * Smoldering Myeloma~* Primary amyloidosis~* Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Elotuzumab + Lenalidomide/Dexamethasone (Type: EXPERIMENTAL): Elotuzumab 10 mg/kg solution intravenously weekly in cycle 1 and 2, then every other week, Lenalidomide 25 mg tablet by mouth Days 1-21 of each cycle / Dexamethasone 40 mg tablet by mouth / solution intravenously weekly until progression or discontinuation of Elotuzumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Active moderate to severe atopic dermatitis defined by Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), Body surface area (BSA), and pruritus.~* Candidate for systemic therapy or have recently required systemic therapy for atopic dermatitis.~* Able to tolerate topical corticosteroids for atopic dermatitis lesions.~Exclusion Criteria:~* Prior exposure to any Janus kinase (JAK) inhibitor.~* Unable or unwilling to discontinue current atopic dermatitis (AD) treatments prior to the study.~* Requirement of prohibited medications during the study.~* Female participant who is pregnant, breastfeeding, or considering pregnancy during the study.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Upadacitinib Dose A is administered once daily along with Topical Corticosteroids (TCS).
- Arm B (Type: EXPERIMENTAL): Upadacitinib Dose B is administered once daily along with Topical Corticosteroids (TCS).
- Arm C (Type: EXPERIMENTAL): Placebo administered once daily and TCS followed by Upadacitinib Dose A once daily along with TCS.
- Arm D (Type: EXPERIMENTAL): Placebo administered once daily and TCS followed by Upadacitinib Dose B once daily along with TCS.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Bio HRV Liquid Vaccine Given to Infants (Vietnam)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or female infant between, and including, 6 and 10 weeks of age with a birth weight of \> 2000 grams.~* Written informed consent obtained from the parent or guardian of the subject.~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the HRV liquid vaccine or placebo within 30 days preceding the first dose of HRV liquid vaccine or placebo, or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs since birth.~* Planned administration/ administration of a vaccines not foreseen by the study protocol except for DTPw, HBV and OPV vaccines within 14 days before each dose of HRV liquid vaccine or placebo and ending 14 days after.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).~* History of allergic disease or reactions likely to be exacerbated by any component of the HRV liquid vaccine or placebo.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 10 Weeks
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic or cytologic diagnosis of NSCLC Stage IIIB (with pleural effusion and/or positive supraclavicular lymph nodes) or Stage IV prior to induction therapy.~* Participants must have had 1 of the following induction therapies for treatment for Stage IIIB (with pleural effusion and/or positive supraclavicular lymph nodes) or IV NSCLC: Gemcitabine plus carboplatin, paclitaxel plus carboplatin, or docetaxel plus carboplatin, gemcitabine plus cisplatin, paclitaxel plus cisplatin or docetaxel plus cisplatin.~* Participants must have received only 1 chemotherapeutic doublet lasting precisely 4 cycles.~* Induction regimens must be based on 21-day cycles.~* Documented evidence of a tumor response of complete response (CR), partial response (PR), or stable disease (SD). Tumor assessment must occur between Cycle 4 (Day 1) of induction therapy and the date of randomization. This response does not have to be confirmed in order for the participant to be randomized. Positron emission tomography (PET) scans and ultrasounds may not be used for lesion measurements for response determination.~Exclusion Criteria:~* With the exception of those chemotherapies listed as inclusion criterion, participants will not be included if they have received prior systemic anticancer therapy (including adjuvant early-stage treatment for NSCLC) or any systemic treatment for any other cancer.~* Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.~* Inability to comply with protocol or study procedures.~* A serious concomitant systemic disorder that would compromise the participant's ability to complete the study.~* A serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease, as defined by the New York Heart Association Class III or IV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed and Best Supportive Care (Type: EXPERIMENTAL): None
- Placebo and Best Supportive Care (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Males \& females, age ≥ 18 years (or minimum adult age as determined by local regulatory authorities)~2. Screening plasma HIV-1 RNA ≥ 5,000 copies/mL~3. CD4+ lymphocyte cell count ≥ 300 cells/mm3 and no documented count \< or = 250 cells/mm3~4. Has not taken any antiretroviral therapy (ART) w/in 12 wks of Early Screening Visit~5. Exclusive CCR5-tropic virus as determined by Trofile™ Assay at Early Screening Visit~6. Clinically normal or not clinically significant (NCS) resting electrocardiogram~7. Women of reproductive potential must have a negative serum pregnancy test at Late Screening Visit \& a negative urine pregnancy test w/in 72 hrs prior to first dose of study medication, \& be non-lactating. Male \& female subjects must agree not to participate in a conception process from Early Screening Visit through Day 59.~Exclusion Criteria:~1. CXCR4 tropic virus or dual/mixed tropic (R5X4) virus determined by the Trofile™ Assay.~2. Females who are pregnant, lactating or breastfeeding, or who plan to become pregnant during the study.~3. History of active hepatitis within the previous 24 wks~4. Prior use of any entry, attachment, CCR5 co-receptor or fusion inhibitor, including PRO 140, experimental or approved.~5. Any immunization or vaccination (including influenza vaccine) within 30 days prior to administration of study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: ACTIVE_COMPARATOR): PRO 140 for three single SC doses: Days 1, 8, and 15
- Arm 2 (Type: ACTIVE_COMPARATOR): PRO 140 for three single SC doses: Days 1, 8 and 15
- Arm 3 (Type: ACTIVE_COMPARATOR): PRO 140 for two single SC doses: Days 1 and 15 plus one SC dose of PBO at Day 8
- Arm 4 (Type: PLACEBO_COMPARATOR): PBO for three single SC doses: Days 1, 8 and 15

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Primary Inclusion Criteria:~* The patient has a bone mineral density T-score ≤ 2.5 at the lumbar spine or hip (femoral neck) by dual energy x-ray absorptiometry (DXA). Women with a bone mineral density T-score of 2.0 or lower and a prior low-trauma forearm, humerus, vertebral, sacral, pelvic, hip, femoral, or tibial fracture within the past 5 years, or who have an additional risk factor such as age 65 or greater or a strong maternal history of osteoporosis defined as a fracture related to osteoporosis or osteoporosis itself as determined by BMD criteria, are also study candidates.~* The patient is in good general health as determined by medical history and physical examination and is without evidence of clinically significant abnormality in the opinion of the Investigator.~Primary Exclusion Criteria:~* History of bone disorders (e.g., Paget's disease) other than postmenopausal osteoporosis.~* Prior treatment with approved or as yet unapproved bone-acting investigational agents.~* History of carcinoma, nephrolithiasis or urolithiasis within the past five years or osteosarcoma at any time.~* History of radiotherapy (radiation therapy).

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- BA058 20 µg (Type: EXPERIMENTAL): None
- BA058 40 µg (Type: EXPERIMENTAL): None
- BA058 80 µg (Type: EXPERIMENTAL): None
- teriparatide (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Phase 1: Patients with evaluable or measurable (by MRI or CT) Hodgkin's Disease or Non-Hodgkin's Lymphoma. Phase 2: Patients with Measurable Non-Hodgkin's Lymphomas (Indolent or Aggressive) only. - Patients with Indolent NHL must be relapsed or refractory to at least one prior line of therapy (CHOP, CVP, chlorambucil or fludaribine). Prior treatment with Rituximab is required. - Patients with Aggressive NHL refractory to (or relapsed from) at least one CHOP-based therapy who have had prior treatment with Rituximab and who are not candidates for high-dose chemotherapy or autologous stem cell transplantation. - ECOG performance status 0-2 - Autologous stem cell transplant recipients are eligible if 100 days have elapsed since procedure. Exclusion Criteria: Phase 1: History of prior radioimmunotherapy (Bexxar, Zevalin); These patients ARE permitted in the Phase 2 trial. - Current active malignancy besides NHL, except excised non-melanoma skin cancer, in-situ cervical or bladder cancer or early stage prostate cancer. - Patients with leptomeningeal of CNS lymphoma - Known allergy to and/or receipt of treatments contraindicated by administration of G-CSF - Patients with active Hepatitis B or C, or patients with HIV infection. - Pregnant or breast-feeding females. - Previous treatment with a KSP inhibitor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1 Dose Escalation (Type: EXPERIMENTAL): Phase 1 dose escalation without and with GCSF support
- Phase 2 Fixed Dose (Type: EXPERIMENTAL): Phase 2 fixed dose based on Phase I findings stratified by NHL type

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete